Volume 9, Issue 7, July – 2024 International Journal of Innovative Science and Research Technology
ISSN No:-2456-2165 https://doi.org/10.38124/ijisrt/IJISRT24JUL1485

An Integrated Review of Hepatorenal Syndrome

Alwala Nitisha[1]; Jangam Pratyusha[2]; Samala Shika[3]
Malla Reddy College of Pharmacy, Approved by AICTE, PCI& amp; Affiliated to Osmania university, Hyderabad, Maisammaguda, Dhulapally, (Post via Hakimpet), Hyderbad-500100

Abstract:- The purpose of this review was to go over and condense the intricate details that have been updated over time about the diagnosis, etiopathology, definition, and available treatments for hepatorenal syndrome. When individuals have decompensated liver disease, acute kidney injury might have multiple causes, including hormone replacement therapy (HRS). Type 1 and type 2 are the two clinical subtypes of hepatorenal syndrome. Lack of proteinuria, hematuria, or aberrant renal ultrasonography, as well as declining kidney function, are the basis for the diagnosis. Liver transplantation is the best treatment for cases of HRS, but because of the high death rate, very few people get one. In light of the improved understanding of the condition, more hepatorenal syndrome therapeutic options, including pharmacological and non-pharmacological techniques, are also explored.

Keywords:- *Liver Transplant, Cirrhosis, Terlipressin, Kidney Failure, Diagnostic, Treatment, and Hepatorenal Syndrome*.

I. INTRODUCTION

A patient with liver cirrhosis might progress to either compensated or decompensated stages. In decompensated cirrhosis, the prognosis is two years instead of twelve, with the hallmarks of ascites, variceal bleeding, and hepatic encephalopathy.

Changes from a compensated to a decompensated stage are primarily caused by portal hypertension. Hepatorenal syndrome (HRS), spontaneous bacterial peritonitis, refractory ascites, variceal bleeding, and the return of hepatic encephalopathy all reduce survival.

Due to the extremely bad prognosis of hepatorenal syndrome, it is imperative to identify it early, understand the illness, rule out other possible causes of renal failure, and start medical treatment or a transplant as soon as possible.[1]

- *Definition*:

People with severe liver illness may experience hepatorenal syndrome (HRS), a kind of decreased kidney function. Serum creatinine doubles twice as quickly as renal failure progresses in type 1 HRS. Ascites, or fluid buildup in the belly, is linked to Type 2 HRS and is not improved by taking prescription diuretics.[2]

- *Symptoms*:

Individuals with hepatorenal syndrome will have a variety of nonspecific symptoms including Fatigue, stomach ache, and a generalized feeling of being unwell are among the nonspecific symptoms that people with hepatorenal syndrome may experience (malaise).

A accumulation of fluid in the abdomen (ascites), a yellowing of the skin and whites of the eyes (jaundice), an enlarged spleen (splenomegaly), and an enlarged, extremely tender liver (hepatomegaly) are some symptoms of severe liver disease that affect affected persons.[3]

- *Causes*:

Hepatorenal syndrome's precise cause is unknown. It happens to people with advanced liver illness, particularly to those who have cirrhosis, which is a liver malfunction and scarring condition.

Renal vasoconstriction, or narrowing of the blood arteries supplying the kidneys, is a hallmark of people with hepatorenal syndrome. This reduces blood flow to the kidneys, ultimately affecting kidney function.[3]

- *Epidemology*:

AKI is one of the most prevalent side effects of decompensated cirrhosis; it affects 20–50% of cirrhotic patients who are hospitalized for disease-related issues, and it develops in 50% of cirrhotic patients who pass away. After one year of diagnosis, 20% of individuals with severe cirrhosis will get HRS, and 40% will experience it over the course of the following five years. While accounting for 15–30% of all AKI cases, HRS-AKI is the type with the worst prognosis.[1]

II. PATHOPHYSIOLOGY

The peripheral arterial vasodilation theory, which contends that splanchnic vasodilation resulting from portal hypertension with cirrhosis is the trigger for the development of HRS, is the most widely recognized explanation for the pathophysiology of HRS. Though to a lesser extent, other vasodilator substances such as glucagon, carbon monoxide, vasodilator peptides, and others also contribute to splanchnic vasodilation; nitric oxide is the primary mediator.

Blood gets trapped in the splanchnic vascular bed due to splanchnic vasodilation, which lowers the effective arterial blood volume ("arterial underfilling"). To counteract the decrease in systemic vascular resistance, cardiac output and contractility increase in compensated cirrhosis. This maintains a temporary constant effective arterial blood volume. Nonetheless, as splanchnic vasodilation progresses, the effective arterial blood volume gradually falls.

ISSN No:-2456-2165 https://doi.org/10.38124/ijisrt/IJISRT24JUL1485

There may be a decrease in cardiac output as cirrhotic cardiomyopathy advances. Declining effective arterial blood volume causes compensatory neurohormonal vasoconstrictor systems, such as the renin-angiotensin-aldosterone system (RAAS), arginine vasopressin, and sympathetic nervous system (SNS), to increase.

Due to sodium and water retention, ascites and hyponatraemia are caused, along with vasoconstriction of the renal, cerebral, and peripheral vascular beds. The effects of the neurohormonal vasoconstrictor systems in the kidneys can first be counterbalanced by local renal vasodilators, such as prostaglandins. Ultimately, this is insufficient since the tone of the renal vasoconstrictor is predominate. Renal blood flow is significantly reduced as a result of this process, which lowers glomerular filtration rate (GFR) and results in HRS.[4]



Fig 1 The Effects of the Neurohormonal Vasoconstrictor Systems

III. DIAGNOSTIC CRITERIA FOR HSR

➢ *Important Criteria*

- Portal hypertension and severe hepatic failure in conjunction with acute or chronic liver illness.
- There are two markers of poor GFR: serum creatinine > 1.5 mg/dL and 24-hour creatinine clearance < 40 mL/min.
- No renal or gastrointestinal fluid losses (weight loss > 500 g/day for several days in patients with ascites without peripheral oedema or 1000 g/day in patients with peripheral oedema), frequent vomiting or severe diarrhoea, absence of shock, ongoing bacterial infection, or recent or current nephrotoxic drug treatment.
- There was no sustained improvement in renal function (reduction in serum creatinine < 1.5 mg/dL or increase in creatinine clearan ce to > 40 mL/min) after the discontinuation of diuretics and plasma volume augmentation with 1.5 L of isotonic saline.
- Proteinuria less than 500 mg/dL and absence of sonographic signs of parenchymal renal disease or obstructive uropathy.

ISSN No:-2456-2165 https://doi.org/10.38124/ijisrt/IJISRT24JUL1485

➢ *New Diagnostic Criteria for HSR:*

- Cirrhosis and Ascites.
- A serum creatinine level more than 1.5 mg/dL or 133 μ mol/L.
- The serum creatinine level fell to a level of ≤ 133 μmol/L; no improvement was observed after stopping diuretics and increasing albumin volume for at least two days. One gram of albumin per kilogram of body weight per day, up to a daily maximum of 100 g, is the suggested dosage.
- Shows no symptoms of shock.
- No past or present history of treatment with nephrotoxic medications.
- The lack of parenchymal kidney disease, as evidenced by aberrant renal ultrasonography, more than 500 mg/day of proteinuria, and microscopic haematuria (more than 50 red blood cells per high power field).

➢ *Therapy Options Available:*

- *Liver Transplantation*

Patients with reversible HRS-AKI are thought to benefit most from liver transplantation (LT), as it addresses the underlying liver insufficiency that leads to the condition. This is rarely the case in practice, as organ shortages, the fact that most patients are not good candidates for transplants, and other factors lower the status of patients with HRS-AKI on the LT list.

IV. PHARMACOLOGICAL THERAPY

➢ *Volume Expansion:*

It is believed that albumin is a significant plasma expander for the treatment of HRS-AKI. In the most severe forms of liver illness, albumin either increases or maintains heart rate. Albumin may also have anti-inflammatory properties based on preclinical study.

➢ *Vasoconstrictors*:

Vasoconstrictive part of the treatment can be administered in a number of ways. Alpha-adrenergic receptor agonists include norepinephrine and midodrine. They function by binding to vascular smooth muscle cells' alpha-1-adrenergic receptors, which results in vasoconstriction. By preventing the production of glucagon and other vasodilator peptides, octreotide, a somatostatin analog, produces vasoconstriction in the portal, splanchnic, and systemic circulations.

Table 1 Pharmacological Treatment of Hepatorenal Syndrome

MEDICATION	MECHANISM	DOSAGE	COMMENTS
Midodrine	Alpha agonist ↑ blood pressure ↑ renal perfusion pressure	Start with 5 mg tid and titrate to maintain a mean arterial pressure > 70 mm Hg	Used in combination with octreotide. Combination is inferior to continuous infusion of terlipressin.
Octreotide	Long-acting analogue of somatostatin ↓ splanchnic vasodilatation	Continuous intravenous infusion of 25 μg stat followed by 25 μg/h; or 100 μg tid subcutaneously	Octreotide alone has been shown to be ineffective as a treatment for HRS.
Vasopressin	V1 receptor agonist. Vasoconstriction of systemic and splanch-nic circulations		Not commonly used because of ischemic side effects
Terlipressin	Vasopressin analogue	0.5–2 mg q4–6 h IV; or continuous intravenous infusion at 2–12 mg/day	Less ischemic side effects than vasopressin. Continuous infusion is better tolerated and more effective at lower doses than IV boluses.
Norepinephrine	Alpha, beta-adrenergic agonist. Systemic vasoconstriction	0.5–3 mg/h	Reversal of HRS. No significant ischemic side effects. Equally efficacious as terlipressin.

HRS, Hepatorenal Syndrome; IV, Intravenous.

ISSN No:-2456-2165 https://doi.org/10.38124/ijisrt/IJISRT24JUL1485

➢ *Potential Adverse Events of Pharmacologic Therapy*

- *Volume Expanders*

Excessive resuscitation with albumin in patients with decompensated cirrhosis and portal hypertension might result in intravascular volume overload and cardiac compromise, necessitating judicious administration and monitoring.

- *Vasoconstrictors*

The most frequent adverse reactions to midodrine in controlled trials included chills, paresthesia, sitting and supine hypertension, itching (mostly scalp), desire to urinate, urine retention, and frequent urination. Patients may have headaches, nausea, diarrhea, arthralgia, asthenia, hyperhidrosis, peripheral edema, increased blood sugar, emesis, dyspepsia, sinusitis, and osteoarthritis when taking octreotide. Combining midodrine and octreotide has the advantage of not requiring administration in an intensive care unit. Digital and reversible myocardial ischemia are often associated with norepinephrine. As mentioned previously, norepinephrine infusion should only be utilized in the intensive care unit and requires strict hemodynamic monitoring.[5]

V. DISCUSSION

A growing corpus of research published in the last ten years indicates that vasoconstrictors are used to treat renal failure in patients with type 1 or type 2 HRS. The fact that vasoconstrictors are a reliable and secure treatment for severe variceal hemorrhage has been repeatedly emphasized. No appreciable difference was found when terlipressin plus albumin was compared to noradrenaline plus albumin, octreotide plus albumin was compared to placebo plus albumin, or noradrenaline plus albumin was compared to midodrine plus albumin. In all comparison, there was no discernible variation in patient survival or HRS recurrence. The most successful medical intervention for type 1 HRS reversal is intravenous infusion of terlipressin, since subgroup analysis demonstrated that terlipressin outperformed placebo. None of the other comparisons showed any notable variations, though.[5]

VI. CONCLUSIONS

HRS is a result of cirrhosis and portal hypertension, however it carries a high morbidity and fatality rate. A diagnosis and treatment plan should be started as soon as this sickness is discovered. The first-line therapies are vasopressin analogs (terlipressin) and volume expanders (albumin). Transplanting a liver is the final option.

The best medicinal intervention for reversing HRS is found to be terlipressin intravenous infusion. An appropriate substitute is noradrenaline infused intravenously. Research is required as the foundation for creating pharmaceutical plans to decrease HRS relapse and increase patient longevity .The increased knowledge of cirrhosis is causing major changes in the way HRS is approached in these patients. Increased understanding of it not only makes it possible to classify patients more accurately into various HRS groups, but it also makes it possible to identify and start medication sooner, when it is most beneficial.

REFERENCES

[1]. Alicia S. Ojeda-Yuren, Eira Cerda-Reyes, Maria R. Herrero-Maceda, Graciela Castro-Narro, Salvatore Piano, An Integrated Review of the Hepatorenal Syndrome, Volume 22, May–June 2021, 100236.
[2]. Indika R. Ranasinghe, Bashar Sharma, Khalid Bashir, Hepatorenal Syndrome, August 8, 2023.
[3]. Thomas A. Gonwa, MD, Professor of Medicine, Mayo Clinic College of Medicine, Chairman, Department of Transplantation, Mayo Clinic, Florida, for assistance in the preparation of this report, Hepatorenal Syndrome, *09/30/2022.*
[4]. G. Low, G. J. M. Alexander, D. J. Lomas , Hepatorenal Syndrome: Aetiology, Diagnosis, and Treatment , 2015 Jan 12.
[5]. Steven L. Flamm, Kimberly Brown, Hani M. Wadei, Robert S. Brown, Jr., Marcelo Kugelmas, Milagros Samaniego-Picota, Patrizia Burra, Fred Poordad, and Sammy Saab, The Current Management of Hepatorenal Syndrome–Acute Kidney Injury in the United States and the Potential of Terlipressin, 2021 Jul 14.